Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer

Review decision - August 2015 information

Appendix A - RRP decision paper - August 2015 (PDF 68 KB)

Review proposal - June 2015 information

Appendix A - matrix of stakeholders (PDF 98 KB)

Appendix B - GE proposal paper - June 2015 (PDF 224 KB)

Press release information

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): equality impact assessment - guidance development (PDF 76 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): final appraisal determination information

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): final appraisal determination guidance information

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): final appraisal determination guidance (PDF 294 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): response to consultee, commentator and public comments on the ACD (PDF 515 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): consultee and commentator comments on the ACD

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Roche pharmaceuticals (PDF 909 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Breakthrough Breast Cancer (PDF 36 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Royal College of Nursing (PDF 58 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Royal College of Physicians (PDF 238 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Department of Health (PDF 6.9 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): ERG addendum-recalculation of drug costs (PDF 313 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): appraisal consultation

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): appraisal consultation document information

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): evaluation report

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): pre-meeting briefing (PDF 379 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Evidence Review Group report

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Evidence Review Group report (PDF 1.27 MB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): ERG report erratum (PDF 724 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Evidence Review Group report - factual accuracy check (PDF 94 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Roche (PDF 3.05 MB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): clarification

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): NICE clarification letter (PDF 117 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): manufacturer response to the NICE clarification letter (PDF 806 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): NICE second clarification letter (PDF 112 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): manufacturer response to the second NICE clarification letter (PDF 89 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): patient group, professional group and NHS organisation submission statements

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Breakthrough Breast Cancer (PDF 155 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): joint submission from NCRI/Royal College of Physicians/RCR/ACP/JCCO (PDF 174 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): EIA - scoping (PDF 53 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): final scope (PDF 38 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): final matrix (PDF 57 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): institute's response to consultee and commentator comments on the draft scope (PDF 93 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Institute's response to consultee and commentator comments on the draft matrix (PDF 26 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): draft scope (PDF 49 KB)

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): provisional matrix (PDF 58 KB)

Breast cancer (first line) - bevacizumab: final scope (PDF 28 KB)

Breast cancer (first line) - bevacizumab: final matrix of consultees and commentators (PDF 33 KB)

Breast cancer (first line) - bevacizumab: Institute's response to consultee and commentator comments on the draft scope (PDF 53 KB)

Breast cancer (first line) - bevacizumab: Institute's response to consultee and commentator comments on the provisional matrix (PDF 27 KB)

Breast cancer (first line) - bevacizumab: draft scope (for second consultation) (PDF 36 KB)

Breast cancer (first line) - bevacizumab: provisional matrix (PDF 44 KB)

Breast cancer (first line) - bevacizumab: draft scope (PDF 47 KB)

Breast cancer (first line) - bevacizumab: provisional matrix (PDF 44 KB)